MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2025 International Congress

    Findings of motoric and neuro psychological outcome using high frequency stimulations in Parkinsons with STN-DBS

    A. Dabbeta, V. Rama Raju (Hyderabad, India)

    Objective: For testing the likelihood of decreasing psychiatric dyskinesias of STN-DBS, conducting experimentally and through experimental studies we explore the properties of in what best…
  • 2025 International Congress

    Natural compound Protects Dopaminergic Neurons by Targeting Oxidative Stress and Cell Death Pathways in Parkinson’s Disease

    S. Pandey, R. Singh (Lucknow, India)

    Objective: This study aims to evaluate the neuroprotective potential of a natural compound that protects dopaminergic neurons by targeting oxidative stress and cell death pathways…
  • 2025 International Congress

    The Effects of Melatonin in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs

    V. Byroju, J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

    Objective: To assess the efficacy of melatonin on motor symptoms, sleep quality, and quality of life in patients with Parkinson's disease (PD) by performing a…
  • 2025 International Congress

    Dosage Optimization and Treatment Outcomes of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson’s Disease: a single center study

    K. Kakuda, Y. Kimura, K. Ikenaka, H. Mochizuki (Suita, Japan)

    Objective: To optimize the dosage of foslevodopa/foscarbidopa continuous subcutaneous infusion (CSCI) therapy for Parkinson’s disease by identifying dosage differences between the continuation and discontinuation groups.…
  • 2025 International Congress

    Patient And Clinician Perceptions Of Disease Improvement With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In Advanced Parkinson’s – Data From The ELEGANCE Interim Analysis

    N. Smith, B. Amlani (Reading, United Kingdom)

    Objective: To evaluate clinicians’ and patients’ views of the level of improvement in Parkinson’s disease (PD) achieved following up to two years of treatment with…
  • 2025 International Congress

    Comparative Efficacy and Safety of Opicapone in Parkinson’s Disease: An Updated Systematic Review and Meta-Analysis

    A. Abunamoos, Y. Aljazi, F. Qtaishat, A. Rababah, M. Mustafa, F. Alnajjar, M. Alghaniem (Amman, Jordan)

    Objective: To evaluate the efficacy and safety of Opicapone drug in patients with Parkinson’s disease (PD) using an updated systematic review and meta-analysis, including newly published randomized controlled trials…
  • 2025 International Congress

    Single- and Multi-Unit Activity in STN Provides Enhanced Insight into Speech-Related Neural Dynamics in Parkinson’s Patients

    Z. Jourahmad, A. Rohl, J. Greenlee (Iowa City, USA)

    Objective: We aimed to elucidate neural representations in local field potentials (LFP) and single- and multi-unit activity of subthalamic nucleus (STN) neurons during speech tasks,…
  • 2025 International Congress

    Blood-based biomarkers for diagnosis and prediction of Parkinson’s Disease in GBA1 individuals

    M. Avenali, L. Bandirali, S. Caminiti, P. Mitrotti, L. Gallo, R. Stiuso, R. Calabrese, G. Cuconato, C. Galandra, C. Tassorelli, S. Cerri, EM. Valente, F. Blandini (Pavia, Italy)

    Objective: To investigate glucocerebrosidase (GCase) enzymatic activity and different forms of α-synuclein (aggregated -Asyna – and monomeric - Asynm) in peripheral blood mononuclear cells (PBMCs)…
  • 2025 International Congress

    Distinct Peripheral Immune Profiles of Parkinson’s Disease and Multiple System Atrophy

    S. Jo, I. Jang, J. Lee, M. Choi, E. Lee, SJ. Chung (Seoul, Republic of Korea)

    Objective: We aimed to compare peripheral blood mononuclear cell (PBMC) subsets between Parkinson’s disease (PD) and multiple system atrophy (MSA) to identify disease-specific immune signatures…
  • 2025 International Congress

    Plasma P-tau217 detects Alzheimer’s co-pathology and predicts cognitive decline in Parkinson’s disease

    T. Tropea, P. Aldea Stevenson, M. Flitter, D. Meehan, A. Morris, M. Lu, L. Iaccarino, E. Collins, M. Hodsdon, L. Shaw, E. Lee, D. Weintraub, A. Chen-Plotkin, M. Mintun, A. Siderowf (Philadelphia, USA)

    Objective: The objectives of this study are to compare plasma phosphorylated tau-217 (P-tau217) levels in Parkinson’s disease (PD) with versus without Alzheimer’s disease (AD) copathology…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley